Novavax Stock - analyst attention and recent trading set the tone

Novavax stock has been volatile in recent sessions while remaining a focal point for retail traders. This Friday review looks at how NVAX shares have traded over the past week, how the stock sits in the biotech peer group, and what investors are watching next.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 15:59 CET. Details in the imprint.

Novavax (US6707721049) remains a highly traded biotech name on the Nasdaq. With no fresh company news from its own investor relations page or major wire services this week, the focus on Friday shifts to how the stock has behaved relative to the broader vaccine and biotech sector.

How Novavax shares traded this week

Zacks data show that Novavax shares most recently closed at $9.13, down 3.89% from the prior day in a session where the broader market moved higher. That puts the stock modestly below levels seen earlier in the week, underlining its ongoing volatility.

TrendSpider data indicate that the stock is around $9.14, roughly 1.4% lower than 30 days ago, underscoring a relatively flat but choppy month for the name. Short-term traders continue to respond quickly to any sentiment shifts in the biotech and vaccine space.

Position in the biotech peer group

Within the US biotech universe, Novavax remains a relatively small but visible player, especially among companies tied to vaccines and infectious disease. Market data services track a market capitalization in the roughly mid-hundreds of millions of dollars, far below large peers like Moderna or Pfizer.

That size difference translates into higher share-price sensitivity for Novavax when compared with large integrated pharma groups. Moves of several percent in a single session are common in this segment, particularly when sentiment on pipelines or funding swings.

The business and revenue drivers

Novavax generates revenue primarily from its protein-based vaccines and related agreements, historically led by its COVID-19 vaccine franchise. Company materials emphasize ongoing work on updated COVID formulations, combination vaccines and other respiratory targets, as well as partnerships and license deals.

Unlike diversified pharmaceutical majors, Novavax is still highly dependent on a limited number of products and contracts. That concentration keeps the equity particularly exposed to regulatory decisions, public-health demand trends and negotiations with governments and health organizations.

What the company sells

At the core of the story is Novavax’s protein-based COVID-19 vaccine, marketed in various regions under names such as Nuvaxovid, alongside its broader portfolio of vaccine candidates. The company focuses on recombinant nanoparticle technology combined with proprietary adjuvants to stimulate immune responses.

Where the stock trades today

Novavax shares (US6707721049) trade on the Nasdaq at $9.14 as of 06/19/2026, 15:30 CET.

Key facts on Novavax stock

• Company: Novavax Inc.
• ISIN: US6707721049
• WKN: A2PKMZ
• Ticker: NVAX
• Venue: Nasdaq
• Price (as of 06/19/2026, 15:30 CET): 9.14 USD
• Market cap: about 0.8 billion USD (as of 06/19/2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: not a member of major indices such as the S&P 500 or Nasdaq-100
• Next earnings date: 08/05/2026 (company calendar and data providers)

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.